Danaher soars to record quarter; Healthcare reform will benefit med tech, analysts say;

@FierceMedDev: Alere's proxy fight gets personal in latest round. More | Follow @FierceMedDev

 @MarkHFierce: The clock is ticking. Send in your 2013 FMD Fierce 15 nominations. Submit now | Follow @MarkHFierce

@DamianFierce: Quest dims revenue outlook as it sells stake in J&J cancer drug. Story | Follow @DamianFierce

> Danaher ($DHR) hauled in a record $4.7 billion in the second quarter, 4% over the same period last year, and net income rose 3.5% to $616.8 million. Results

> Despite all the hand-wringing over the 2.3% excise tax, RBC Capital Markets analysts say many medical device companies will benefit once the Affordable Care Act's insurance mandates kick in next year. Report

> TB Biosciences has raised a $1.5 million Series A to develop a point-of-care diagnostic for tuberculosis. Release

> Illumina ($ILMN) has launched a phasing analysis offering for its whole-genome mapping services, allowing researchers to identify segments of connected variants within a gene. News

> In an interview with The Los Angeles Times, Ambry Genetics CEO Charles Dunlop said Myriad Genetics' ($MYGN) lawsuit against his company is without merit. "I don't know what they're doing other than just bullying people," he said. Article

> India's FDA sealed the plant of a local device manufacturer after finding that some of its orthopedic implants weren't sterile. Story

> In a study published in the Journal of the American College of Cardiology, covered stents showed better patency at 12 months than standard bare-metal implants. Item

> Diagnostics outfit Venaxis ($APPY) has notched some positive early results for the APPY1 Test, designed to gauge a patient's risk of appendicitis, and the company said it's on track to file for FDA approval. More

Biotech News

@FierceBiotech: After Eylea win, Regeneron execs puzzle over R&D scale-up challenge. Article | Follow @FierceBiotech

 @JohnCFierce: Ensemble hasn't raised VC $$ since 2007--which is impressive. Funded by marquee collaborations. | Follow @JohnCFierce

 @EmilyMFierce: ICYMI: NIH confirms it's shelving India drug trials in wake of new regs. Editor's corner | Follow @EmilyMFierce

> Booming Alexion looks to Ensemble platform for ultrarare disease programs. Article

> OncoMed extends the biotech IPO winning streak with $82M haul. News

Pharma News

@FiercePharma: Merck taps India's Lupin to market pneumococcal vax under new name. In U.S., brand = Pneumovax 23. More | Follow @FiercePharma

 @CarlyHFierce: Vivus holding its annual meeting this morning. Stay tuned for the end of the proxy fight with First Manhattan--and its outcome. | Follow @CarlyHFierce

> Novartis under U.S. scrutiny for Gilenya marketing tactics. Story

> Deaths force Celgene to stop Revlimid CLL trial in its tracks. News

> Lilly freezes salaries ahead of patent loss for Cymbalta. Report

Pharma Manufacturing News

 @EricPFierce: From FierceVaccines.com: ABC's appointment of Jenny McCarthy sparks media furor. News | Follow @EricPFierce

> UAE expects big growth in generic drug production. Item

> Penn Pharma to expand plant opened in May. Report

> China regulators pledge new crackdown on counterfeit drug operations. More

> J&J says it has upped its quality game across all 120 plants. Article

> Cispharma warning letter says injury investigation inadequate. Story

Vaccines News

> Gates-backed device extends cold chain to rural areas. Report

> Bio Farma taps Artes for VLP technology. Item

> ABC's appointment of Jenny McCarthy sparks media furor. More

> New data supports vaccinating gay men against HPV. Story

> Sanofi starts up dengue vaccine plant to maintain edge over Takeda. Article

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.